University of Central Florida

STARS
UCF Patents

Technology Transfer

8-5-2003

Treatment of breast cancer
Delbert Miles
University of Central Florida

Elena Goun
Perm State University

Krasnych Pertrovna
Perm State University

Pimenova Valentinovna
Perm State University

Solodnikov Yyrjevitsh
Perm State University

Find similar works at: https://stars.library.ucf.edu/patents
University of Central Florida Libraries http://library.ucf.edu
This Patent is brought to you for free and open access by the Technology Transfer at STARS. It has been accepted for
inclusion in UCF Patents by an authorized administrator of STARS. For more information, please contact
STARS@ucf.edu.

Recommended Citation
Miles, Delbert; Goun, Elena; Pertrovna, Krasnych; Valentinovna, Pimenova; and Yyrjevitsh, Solodnikov,
"Treatment of breast cancer" (2003). UCF Patents. 617.
https://stars.library.ucf.edu/patents/617

Illlll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
US006602907B 1

(12)

United States Patent

(10)

Miles et al.

(45)

(54)

TREATMENT OF BREAST CANCER

(75)

Inventors: Howard Miles, Winter Springs, FL
(US); Solodnikov Sergey Yurjevich,
Perm (RU); Krasnykh Olga Petrovna,
Perm (RU); Pimenova Elena
Valentinovna, Perm (RU); Elena A.
Goun, Stanford, CA (US)

(73)

Assignee: University of Central Florida,
Orlando, FL (US)

( *)

Notice:

(21)

Appl. No.: 10/164,541

(22)

Filed:

( 60)

Provisional application No. 60/296,823, filed on Jun. 8,
2001.

(51)
(52)

Int. Cl.7 .............................................. A61K 31/277
U.S. Cl. ......................... 514/523; 514/557; 560/19;
562/459
Field of Search ................................. 514/523, 557;
562/459; 560/19

Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 17 days.

Jun. 7, 2002
Related U.S. Application Data

(58)

References Cited

(56)

U.S. PATENT DOCUMENTS
5,308,852
5,334,612
5,580,896
6,048,896
6,066,670
6,083,985
6,121,450

A
A
A
A
A
A
A

* 5/1994 Girard et al. . .. ... ... ... ... 514/336
8/1994 Kalden ....................... 514/440

* 12/1996 Horwell et al. ............. 514/419
*

4/2000
5/2000
7/2000
9/2000

Giordani ..................... 514/545
Brown ....................... 514/557
Yonemoto et al. .......... 514/568
Jones ... ... ... .. ... ... ... ... .. . 546/81

Patent No.:
US 6,602,907 Bl
Date of Patent:
Aug. 5, 2003

6,180,651 Bl
6,232,312 Bl

1/2001 Nicolai ....................... 514/336
5/2001 Pamukcu ................. 514/237.5

* cited by examiner
Primary Examiner-Joseph K. McKane
Assistant Examiner-Robert Shiao
(74) Attorney, Agent, or Firm-Brian S. Steinberger;
Roland A Dexter; Law Offices of Brian S. Steinberger, P.A.

ABSTRACT
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Compounds of the class of 4-oxo-butenoic acid derivatives
are disclosed along with the surprising use property of these
compounds as a anti-tumor agents in humans against breast
carcinoma, which include: 2-(N'-Fluoren-9-ylidenehydrazino )-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl
ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-(4me thy 1-benzoy 1)-5-oxo-2,5-dihydro- lH-pyrrole-2carboxylic acid methyl ester (lF-07), 4-(4-Methoxyphenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid (3F10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,
6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15),
and 4,4-Dihydroxy-5-( 4-methyl-benzoyl)-2-phenyl-2,4dihydro-pyrazol-3-one (3F-16) as well as some novel
derivatives of these compounds claimed (see Table 2). The
invention also encompasses a class of the compounds with
the novel property of anti-tumor activity against human
breast cancer, which includes the following compounds
4-( 4-Ethoxy-pheny1)-2-(N'-fiuoren-9-ylidene-hydrazino )-2hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N'-[1(4-Chloro-phenyl)-ethylidene ]-hydrazino }-4-oxo-4-phenylbut-2-enoic acid methyl ester (OF-20); 2-(N'-Fluoren-9ylidene-hydrazino )-4-oxo-4-phenyl-but-2-enoic acid methyl
ester (lF-04); and 4-Chloro-4-( 4-ethoxy-phenyl)-2(fiuoren-9-ylidene-hydrazono)-but-3-enoic acid methyl
ester (3F-19).

3 Claims, 2 Drawing Sheets
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derivatives of carboxylic acid (column 9, line 31) and
pyrrolidine (column 7, line 24);
Brown (U.S. Pat. No. 6,066,670) describes an anti-viral
This application claims benefit of Ser. No. 60/296,823
admixture containing crotonic acid for treating tumors
filed Jun. 8, 2001.
(see Abstract);
5
FIELD OF THE INVENTION
Harwell, et al (U.S. Pat. No. 5,580,896) discloses many
4-oxo-2-butenoic acid derivatives (column 13, lines
This invention relates to novel 4-oxo-butenoic acid
21-59;
also in columns 15+, examples 25,26,32,34,40,
derivatives and to the use of these compounds and related
43-46,77-79, 97,99,103,106,), which are useful for
compounds with novel biological activity in humans as
inhibiting colorectal cancer, i.e., colon cancer
therapeutic means for the prevention and treatment of the 10
(Abstract); and,
human breast cancer and claims the benefit of priority of
Giordani, et al (U.S. Pat. No. 5,580,890) discloses 4-oxoU.S. Provisional Application Serial No. 60/296,823 filed
2-butenoic acid derivatives said to be useful for treatJun. 8, 2001.
ment of AIDS (column 1, line 8 and column 2, line 61;
15
BACKGROUND OF THE INVENTION
and,
Yonemeto,
et al (U.S. Pat. No. 6,083,985) recites a
Cancer is a global killer of humans with breast cancer
number of anti-tumor or anti-AIDS agents that include
among the leaders of killing humans yearly. Breast cancer is
butenoic acid derivatives.
the primary killer of women. One in eight American women
The U.S. patent literature has many disclosures of
will develop breast cancer in her lifetime. In 2001, an
estimated 192,700 women in the U.S. will be diagnosed with 20 butanoic acid derivatives including:
Nicolai, et al (U.S. Pat. No. 6,180,651) discloses many
invasive breast cancer and 42,600 with in situ (tumors
anti-inflammatory and analgesic compounds, including
contained in the milk ducts). An estimated 40,000 will die
adenocarcinoma (column 1, line 55), which includes
from the disease.
heterocyclic alcohol-esters (column 11, lines 1-16) and
An estimated 3 million women in the U.S. today are living
butanoic acid derivatives (many Examples including 47
with breast cancer of which 2 million have been diagnosed 25
through 162);
with the disease and I million have the disease but do not yet
know it.
Girard, et al (U.S. Pat. No. 5,308,852) discloses many
compounds including butanoic acid derivatives (see
The incidence of breast cancer in the U.S. has more than
Methods B and C of schemes II and III) which comdoubled in the past 30 years. In 1964, the lifetime risk was
1 in 20. Today it's 1 in 8. Breast cancer is the most 30
pounds which are said to inhibit tumor metastasis
commonly diagnosed cancer in women in both America and
(column 7, line 56 and column 8, line 4); and,
worldwide. Breast cancer rates are the highest in industriFrechette (U.S. Pat. No. 5,696,117), Frechette(U.S. Pat.
alized countries. It is estimated that 1.2 million new diagNo. 5,854,242) and Frechette (U.S. Pat. No. 5,707,990)
noses and 500,000 deaths from breast cancer will occur
describe 148 benzoxazine and pyrido-oxazine heteroworldwide this year. Further, it appears that breast cancer is 35
cyclics as anti-bacterial compounds.
the leading cause of death for American women of ages 25
It appears from the foregoing that the derivatives of
to 55 years.
4-oxo-butanoic acid of interest are not disclosed and thus
No vaccine or other universally successful method for the
there is no report of their activity against human breast
prevention or treatment of breast cancer is currently availcancer.
able. Management of the disease currently relies on a 40
Consequently, there is a need for an anti-cancer drug for
combination of early diagnosis (through routine breast
humans that mitigates the above mentioned disadvantages of
screening procedures) and aggressive treatment, which may
current drug therapy and effectiveness against human breast
include one or more of a variety of treatments such as
cancer.
surgery, radiotherapy, chemotherapy and hormone therapy.
SUMMARY OF THE INVENTION
The course of treatment for a particular breast cancer is often 45
selected based on a variety of prognostic parameters, includThe first objective of the present invention is to provide a
ing an analysis of specific tumor markers. {Porter-Jordan
drug effective for treatment of human breast cancer.
and Lippman, Breast Cancer 8:73-100 (1994)}. However,
Another object of this invention is to provide novel 4-oxothe use of established markers often leads to a result that is
butenoic acid derivatives.
difficult to interpret, and the high mortality observed in
A further object of this invention is to provide 4-oxo50
breast cancer patients indicates that improvements are
butenoic acid derivatives with novel activity against human
needed in the treatment, diagnosis and prevention of the
breast cancer.
disease.
A preferred embodiment of the invention encompasses a
Accordingly, there is a need for improved methods for
class of compounds having the property of anti-tumor activchemotherapy for breast cancer. The present invention fulity against human breast cancer comprising the novel struc55
fills this need and further provides other related advantages.
tures of 4-oxo-butenoic derivatives and more specifically
those derivatives: 2-(N'-Fluoren-9-ylidene-hydrazino)-5,5The U.S. patent literature has many disclosures of oxodimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06); 1-(2,
butenoic ( crotonic) acid derivatives:
4-Dime thy 1-p heny1)-2,4-dih ydroxy-3-( 4-me thy1-benzo y1)Pamukci (U.S. Pat. No. 6,232,312) describes crotonic acid
derivatives (column 22, lines 43-58) for the treatment 60 5-o xo-2,5-dih ydro- lH-pyrro le-2-carboxy lic acid methyl
ester (lF-07); 4-( 4-Methoxy-phenyl)-2,4-dioxo-3-(phenylof colonic polyps;
hydrazono )-butyric acid (3F-10); 4-( 4-Chloro-phenyl)-2,4Jones et al (U.S. Pat. No. 6,121,450) discloses crotonic
dioxo-3-(phenyl-hydrazono )-butyric acid ethyl ester (3Facid derivatives (column 8, tine 34; column 78, line 24
11); 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafiuoro-4-methoxyand at example 34 as steroid modifiers in treating breast
phenyl)-but-2-enoic acid (3F-15); and 4,4-Dihydroxy-5-(4cancer (column 1, lines 55-58);
65 methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3FKalden, et al (U.S. Pat. No. 5,334,612) discloses com16) as well as novel derivatives of these compounds (see
Table 2).
pounds said to be useful for treating AIDS including
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The use of the following compounds for humans as
therapeutic means for the eradication of human breast cancer
further encompasses the following: 4-( 4-Ethoxy-phenyl)-2(N'-fiuoren-9-y lidene-hydrazino )-2-hydroxy-4-oxo-butyric
acid methyl ester (OF-13); 2-{N'-[1-( 4-Chloro-phenyl)- 5
ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04); and
4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lidenehydrazono )-but-3-enoic acid methyl ester (3F-19).
10
Further objects and advantages of this invention will be
apparent from the following detailed description of presently
preferred embodiments, which are illustrated structurally in
the accompanying drawings.

the compound designated as lF-07 is 1-(2,4-Dimethylphenyl)-2,4-dihydroxy-3-( 4-methyl-benzoyl)-5-oxo-2,
5-dihydro-lH-pyrrole-2-carboxylic acid methyl ester;
the compound designated as 3F-10 is 4-(4-Methoxyphenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid
the compound designated as 3F-11 is 4-(4-Chlorophenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid
ethyl ester;
the compound designated as 3F-15 is 2-Hydroxy-4-oxo4-(2,3,5,6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic
acid and,
the compound designated as 3F-16 is 4,4-Dihydroxy-5( 4-methyl-benzoy 1)-2-pheny1-2,4-dihydro-pyrazol-3one.
15
BRIEF DESCRIPTION OF THE FIGURES.
These compounds have very.high activity against human
breast cancer and a very low toxicity as Lethal Dose 50
FIG. 1 illustrates structurally a chemical compound des(LD 50) in animals. The percent activity and animal toxicity
ignated as OF-06.
for each compound is as follows:
FIG. 2 illustrates structurally a chemical compound desOF-06 (100% against human breast carcmoma and
20
ignated as lF-07.
LD 50 >3000 mg/kg);
FIG. 3 illustrates structurally a chemical compound deslF-07
(100% against human breast carcmoma and
ignated as 3F-10
LD
>500 mg/kg);
50
FIG. 4 illustrates structurally a chemical compound des3F-10 (100% against human breast carcinoma and LD 50 ,
ignated as 3F-11
<750 mg/kg);
FIG. 5 illustrates structurally a chemical compound des- 25
ignated as 3F-15
3F-11 (100% against human breast carcmoma and
LD 50 >2000 mg/kg);
FIG. 6 illustrates structurally a chemical compound designated as 3F-16
3F-15 (100% against human breast carcmoma and
LD 50 >200 mg/kg); and,
30
DESCRIPTION OF THE PREFERRED
3F-16 (100% against human breast carcmoma and
EMBODIMENTS
LD 5 >500 mg/kg)
Before explaining the disclosed embodiments of the
present invention in detail, it is to be understood that the
PREPARATION OF (OF-06).
invention is not limited in its application to the details of the 35
particular arrangement shown since the invention is capable
EXAMPLE 1
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
The preparation of 2-(N'-Fluoren-9-ylidene-hydrazino)-5,
5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06). A
As earlier recited this application has been filed in order
to disclose: new 4-oxo-butenoic acids that have been found 40 solution of 5.0 g (0.02 moles) of 2-hydroxy-5,5-dimethyl4-oxo-hex-2-enoic acid methyl ester (1) (synthesis was
to have high activity against human breast cancer and low
previously published by E. Royals. JAm.Chem.Soc., 1945,
toxicity in animals.
67, 1508) and 3.88 g (0.02 moles) of fiuoren-9-ylideneMore specifically this application is for the novel antihydrazine
(2) in 80 mL of absolute toluene was refluxed for
tumor compounds OF-06, lF-07, 3F-10, 3F-11, 3F-15 and
3F-16 which have been structurally shown in FIGS. 1-6, 45 3 hr 30 min with a Dean-Stark trap (control for the end of
the reaction was carried by TLC). The solution was cooled
respectively, as well as novel derivatives of these comand the precipitate was filtered and recrystallized from
pounds claimed (see Table2) and the activity against human
absolute benzene-hexane (1:1) to give 3.4 g (68% yield) of
breast cancer of compounds OF-13, OF-20, lF-04, and 3F-19
yellow crystals, mp 135-137° C.
also as shown in Table 1 along with anti-tumor activity and
toxicity.
Solubility: highly soluble in DMSO, DMFA,
50
dichloroethane, acetonitrile, slightly soluble in ethanol,
To facilitate a full understanding of the invention:
tetrachloromethane, insoluble in hexane and water.
the compound designated as OF-06 is 2-(N'-Fluoren-9y lidene-hydrazino )-5,5-dimethy1-4-oxo-hex-2-enoic
The synthesis of OF-06 is an example of well known
amination/dehydration reactions.
acid methyl ester;

CH3
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I
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I
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+
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PREPARATION OF (lF-07)
EXAMPLE 2
The preparation of 1-(2,4-Dimethyl-phenyl)-2,4dihydroxy-3-( 4-methy 1-benzoy1)-5-oxo-2,5-dihydro-lHpyrrole-2-carboxylic acid methyl ester (lF-07). To a solution
of 1.65 g (0.0051 moles) of 2-(2,4-diinethyl-phenylamino)4-oxo-4-p-tolyl-but-2-enoic acid methyl ester (1) in 20 mL
of anhydrous chloroform was added 0.68 g (0.0054 moles)
oxalyl chloride. After refluxing for 30 min, 10 mL of
anhydrous hexane was added and 15 ml of solvent was
distilled out. The remainder of the solvent was evaporated
by keeping the flask open for 12 hr. The resulting precipitate
was filtered and recrystallized from dichloroethanetetrachlorometane (1:2) to give 1.25 g (62%) of compound
lF-7 in the form of white crystals, mp 133-135° C.
(decamp.)
Solubility: highly soluble in DMSO, acetonitrile, slightly
soluble in dichloroethane, benzene, insoluble in hexane
tetrachloromethane and water.

H3C~COOCH3

25

Solubility: highly soluble in DMSO, DMFA, slightly
soluble in chloroform, dichloroethane; insoluble in hexanes.
30
H3Co-O-co-cH=1-cooH

+

OH

35

1. (COC1)2,t
2.H20

n,c'¢
0

20

phenyl)-4-oxo-but-2-enoic acid in 300 ml of dioxane small
potions of an aqueous solution prepared from 0.075 moles of
aniline, 0.92 moles of sodium nitrate and 19 ml of concentrated HCl in 90 ml of water (DI) was added. During cooling
11.4 g of sodium acetate was added and the reaction was
kept at the r.t. for 24 hr. Then 2 L of water was added to the
reaction mixture and the resulting precipitate was filtrated
and recrystallized from 1: 1 mixture of dimethyl chloride/
ethyl acetate to give 15.93 g of yellow crystals (60% yield)
with m.p. of 176-177 (decamp).

NH

40
3F-10

45

PREPARATION OF (3F-11)

CH3

EXAMPLE 4
50

lF-7

PREPARATION OF (3F-10)
EXAMPLE 3
The preparation of 4-( 4-Methoxy-phenyl)-2,4-dioxo-3(phenyl-hydrazono)-butyric acid (3F-10). To a hot stirred
solution of 0.075 moles of 2-Hydroxy-4-( 4-methoxy-

65

The preparation of 4-( 4-Chloro-phenyl)-2,4-dioxo-3(phenyl-hydrazono )-butyric acid ethyl ester (3F-11). A solution of 0.5 g (0.0016 moles) of 5-(4-Chloro-benzoyl)-2phenyl-2H-pyrazole-3,4-dione (1) (synthesis was previously
published by Pimenova, E. V; Andreichikov, Yu. S. (1992)
Zh. Org. Khim. 28, 376-89). in 2 mL of anhydrous ethanol
was refluxed for 1 hr. The resulting solution was cooled and
the precipitate was filtered to give 0.48 g (85% yield) of
yellow crystals with m.p. of 141-142° C. (decamp).

US 6,602,907 Bl
7

8

-continued

by Pimenova, E. V; Andreichikov, Yu. S. (1992) Zh. Org.
Khim. 28, 376-89), and 5 mL of water (DI) was kept at the
rt until the solution became colorless and precipitate was
formed. The precipitate was filtered and recrystallized from
dichloroethane-water (10:1) to give 0.45 g (85%) of yellowbrown crystals, mp 134-135° C.

o--ohcooc,n,
N-NHC6Hs

0

5

0
3F-11

PREPARATION OF (3F-15)
EXAMPLE 6
The preparation of 2-Hydroxy-4-oxo-4-(2,3,5,6tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15). A
solution of sodium methoxide was prepared from 0.46 g (20
mmol) of sodium and 30 mL of absolute methanol by
addding small portions to a mixture of 6.35 g (10 mmol) of
1-pentafiuorophenyl-ethanone 1 and 3.54 g (10 mmol) of
dimethyl oxalate 2. After stirring the reaction for 24 hr at rt,
50 mL of 25% aqueous solution of HCl was added. The
resulting mixture was extracted with ether (240 mL),
washed by solution of brine and dried over anhydrous
Na 2 S0 4 . The solvent was removed in vacuum and 10 mL of
saturated solution of NaOH in ethanol was added with
stirring. After 1 hr the reaction mixture was diluted with
water and acidified with H 2 S0 4 (10%) to obtain pH of 1-2.
The resulting precipitate of 3F-15 was filtered and recrystallized from toluene to give 1.73 g (81 % yield) in the form
of white-yellow crystals, mp 155-156° C. (decamp.).
C6Fs-CO-CH3

+ (COOCH3)2

3F-16

25

Solubility: highly soluble in DMSO, dioxane, insoluble in
water.
30

PREPARATION OF (OF-13)
EXAMPLE 8

3) NaOH/C2HsOH
~

F

H 3 C O * j CO-CH=1-cooH
OH

F

20

2)HC1

2

F

15

F
3F-15

PREPARATION OF (3F-16)

The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fiuoren-9ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl
ester-(OF-13). A solution of 5.0 g (0.02 moles) of methyl
4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and
3.88 g (0.02 moles) of fiuorene-9-ylidene-hydrazine (2) in
40
80 mL of absolute benzene and absolute toluene (1:1) was
refluxed for 1 hr 30 min with a Dean-Stark trap (the end of
the reaction was determined by TLC), cooled and the
precipitate was filtered and recrystallized from benzene diethyl ether - hexane mixture (1:3:2) to give 2.65 g (53%
45
yield) of colorless crystals with mp 114-116° C.

EXAMPLE 7

Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, insoluble in hexane. The comThe preparation of 4,4-Dihydroxy-5-(4-methyl-benzoyl)2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16). A solution of 50 pound is not stable in solutions and decomposes quickly
when the solution is heated or stored for a long time with the
0.5 g (0.0017 moles) of 5-( 4-Methyl-benzoyl)-2-phenyl-2Hformation of OF-12.
pyrazole-3,4-dione (1) (synthesis was previously published

+

US 6,602,907 Bl
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-continued

OH
~COOCH3
C2HsO~
,__ _
0

NH

~

OF-13~

-

It is seen from the above that (OF-13) is an intermediate
product during the synthesis of (OF-12).

30

PREPARATION OF (3F-19)
EXAMPLE 9
The preparation of 4 Chloro 4 (4 ethoxy phenyl) 2 (fiuoren
9 ylidene hydrazono) but 3 enoic acid methyl ester (3f-19)
to the solution of 10 g (0.0026 moles of 4 (4 Ethoxy phenyl)
2 (N'fiuoren 9 yliden hydrazine) 4-oxo-but-2-enoic acide

35

methyl ester (OF-12) (synthesis was previously published by
Konyukhova, N. A.; Krasnykh, 0. P.; Aliev, Z. G.;
Maslivets, A. N. Cehmistry ofHetorcyclic Compounds (New
York, N.Y., United States) (Translation of Khimiya
Geterotsiklicheskikh Soedineii) (2001), 37(6), 779-780) in
5 mL of anhydrous benzene 0.3935 g (0.0031 moles) oxalyl
chloride was added. The reaction mixture was refluxed for 1
hour 40 min, cooled, precipitate was filtered and recrystallized from absolute benzene to give 0.62 g (54%) of yellow
crystals, m.p. 163-163 (decom).

C2H5o--O--co-cH2-IT-coocH3
_......N
N

~

OF-12

V----JJ
(COCl)2i

HsC20--0--1=cH-IT-coocH3
Cl

'"°

_......N

~

US 6,602,907 Bl

11

12
TABLE 1
Some Compounds of the Invention

Activity
#
OF-13

Name

Structure

OH

C2HsO~COOMe
0

4-( 4-Ethoxy-phenyl)-2(N' -fluoren-9-y lideneh ydrazino)-2-hydroxy-4oxo-butyric acid methyl

(ATCC HIB123)

LD50,

mg/kg Reference

100%

>1500 Miles et. al. UCF-303A

2-{N'-[1-( 4-Chlorophenyl)-ethylidene ]hydrazino }-4-oxo-4phenyl-but-2-enoic acid
methyl ester

83%

>250 Miles et. al. UCF-311C

2-(N'-Fluoren-9-ylidenehydrazino)-4-oxo-4phenyl-but-2-enoic acid
methyl ester

93%

>1000 Andrejchikov, Yurij S.;
Maslivets, Andrej N.;
Krasnykh, Olga P.;
Aleksandrova, Galina A.;
Vozhakova, Alla V Russ.
(1993), CODEN: RUXXE7
RU 2003655 Cl 19931130
Application: RU 915013322 19910704.

4-Chloro-4-( 4-ethoxyphenyl)-2-(fluoren-9ylidene-hydrazono)-but3-enoic acid methyl ester

100%

>200 Konyukhova, N. A.;
Krasnykh, 0. P.; Aliev,
Z. G.; Maslivets, A. N.
Chemistry of Heterocyclic
Compounds (New York,
NY, United States)
(Translation of Khimi ya
Getero-tsiklicheskikh
Soedinenii) (2001), 37(6),
779-780.

ester

NH....,_
N

~
lJ-----Jl)
OF-20

ffrn,
/NH

0

N

Cl

#

lF-04

0

/NH

ex))
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TABLE 2
Derivatives of 3F-10 having potential anti-tumor activity

#

Name

Structure

3-[ (4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-phenyl-butyric acid methyl ester

0

N....._

Q
Cl

2

3-[ (4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-p-tolyl-butyric acid methyl ester

0

I
N....._

Q
Cl

2,4-Dioxo-4-p-tolyl-3-(p-tolyl-hydrazono)-butyric acid methyl ester

3

0

I
N
'NH

¢
4

3-[ (4-Chloro-phenyl)-hydrazono ]-4-( 4-methoxy-phenyl)-2,4-dioxo-butyric acid methyl ester

0

I
N
'NH

¢
Cl
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TABLE 2-continued
Derivatives of 3F-10 having potential anti-tumor activity

#

Name

Structure

5

4-(4-Chloro-phenyl)-2,4-dioxo-3-(p-tolyl-hydrazono )-butyric acid methyl ester

Cl

OCH3

4-(4-Chloro-phenyl)-3-[(4-methoxy-phenyl)-hydrazono ]-2,4-dioxo-butyric acid methyl ester

0

Cl

4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid ethyl ester

7

I
N
Cl

0

'NH

6
8

2,4-Dioxo-3-(phenyl-hydrazono)-4-p-tolyl-butyric acid ethyl ester
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TABLE 2-continued
Derivatives of 3F-10 having potential anti-tumor activity

#

Name

Structure

2,4-Dioxo-4-phenyl-3-(phenyl-hydrazono)-butyric acid methyl ester

9

0

I
N
'NH

6

10

2,4-Dioxo-3-(phenyl-hydrazono)-4-p-tolyl-butyric acid methyl ester

0

I
N......_
NH

6

11

0

I
N......_
Br

12

4-(4-Bromo-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid methyl ester

0

4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester

0

I
N......_
NH

13

6

OCH3

I
N

0

'NH

6

4-(4-Ethoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester
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TABLE 2-continued
Derivatives of 3F-10 having potential anti-tumor activity

#

Structure

Name

14

4-(4-Fluoro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester

0

I
N
'NH

F

6

15

4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester

Cl

16

3-[ (4-Methoxy-phenyl)-hydrazono ]-2,4-dioxo-4-phenyl-butyric acid methyl ester

0

I
N
'NH

¢
OCH3

17

3-[ (4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-phenyl-butyric acid methyl ester

0

I
N'-.

NH

¢
Cl

CYTOTOXICITY ASSAY
The activity in human breast cancer of the novel compounds (as earlier reported) was realized by the following
procedure which determines the inhibitory effect of test
samples on the growth of human breast cancer cells.
(ATCC HTB123) The HTB123 cells are grown in RPMI
1640 media +10% Fetal bovine serum +4.Sg/L glucose +10
mM HEPES +1.0 mM sodium pyruvate +1% Antibiotic/

60

65

Antimycotic for approximately 48 hours at 37° C./5% C0 2
in the presence of the test compound.
Growth/Non-Growth of the cells (e.g., cell density) is
determined using Promega's MTS/PMS assay system. MTS
(3-( 4,5-dime thylthiazo l-2-yl)-5-(3carboxymethoxypheny1)-2-(4-sulfopheny l)-2H-tetrazolium,
inner salt) is an aqueous compound that is reduced to soluble
formazan by the presence of NADH formed by dehydroge-
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nases present within the HTB123 cells. The absorbance of
USE OF THE INVENTION FOR TREATMENT
the formazan can be measured at 490 nm and is directly
OF HUMAN BREAST CANCER
proportional to the number of living cells present in the
The compounds of the invention, i.e. 4-oxo-butenoic
culture. PMS (Phenazine Methosulfate) is added an electron
acids derivatives and more specifically those novel derivacoupling reagent and greatly increases the rate of reduction. 5
tives: 2-(N'-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4To facilitate a full understanding of the procedure the
oxo-hex-2-enoic acid methyl ester (OF-06); 1-(2,4following definitions are offered:
Dimethy1-pheny1)-2,4-dihydroxy-3-(4-meth y1-benzoy1)-5Test wells-wells containing test sample and Diluted
oxo-2,5-dihydro- lH-pyrrole-2-carboxy lic acid methyl ester
HTB123 cells
(lF-07); 4-( 4-Methoxy-pheny 1)-2,4-dioxo-3-(phenyl10 hydrazono )-butyric acid (3F-10); 4-( 4-Chloro-phenyl)-2,4Test values-absorbance of test wells
dioxo-3-(phenyl-hydrazono )-butyric acid ethyl ester (3FBlank wells-wells containing test sample and HTB 123
11); 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafiuoro-4-methoxymedia (HHTB2-01S); used to obtain background
phenyl)-but-2-enoic acid (3F-15) and, 4,4-Dihydroxy-5-(4absorbance due to test sample
methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3FBlank values-absorbance of blank wells
15
16), as well as all novel derivatives of these compounds
Negative Control-maximal cell growth; results of test
claimed (see Table2), and the additional compounds of Table
samples will be expressed as a percent of the Negative
1 with activity against human breast cancer which include
Control
the following compounds 4-( 4-Ethoxy-phenyl)-2-(N'Positive Control-known inhibitor of HTB 123 cells;
fiuoren-9-ylidene-hydrazino )-2-hydroxy-4-oxo-butyric acid
20
used to validate assay system
methyl ester (OF-13); 2-{N'-[1-(4-Chloro-phenyl)Matrix-solvent that the samples are prepared/diluted in
ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
Assay samples of similar origin and matrix (e.g., methamethyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)nol extraction, methylene chloride extraction, water soluble
4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04); and
samples, etc.) together on the same plate in order to reduce
4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lidenethe number of steps performed per plate.
25 hydrazono)-but-3-enoic acid methyl ester (3F-19).
Blank values will be determined for each sample to
All the compounds are unique in the in vitro treatment of
account for any color contribution due to the sample itself.
humans and can be used as therapeutic means for the
These blank wells must contain the same amount of sample
eradication of tumors from the human breast in a pharmaplus HTB 123 media (no cells). After completion of MTS/
ceutical composition comprising a non-toxic effective
PMS reaction blank values will be subtracted from the test 30 amount of the referenced compound or a tautomeric form
value to obtain a net absorbance that will be used to calculate
thereof or a pharmaceutically acceptable salt thereof or
cell density.
pharmaceutically acceptable solvate thereof, and a pharmaAll results are based upon a comparison to the Negative
ceutically acceptable carrier thereof.
Control value of the plate. The Negative Control must
For administration to man in the curative or prophylactic
contain the same amount of matrix (e.g., solvent) to offset 35
treatment of human breast cancer in vitro dosages of comany destructive effect the matrix may have on the growth of
pounds of the invention will generally be in the range of
the HTB123 cells (allows for baseline values to be set).
from 5 to 500 mg daily for an average adult patient (70 kg).
For most samples, a HTB123 cell growth (diluted two to
Thus for a typical adult patient, individual tablets or capsules
four-fold, depending upon the appearance of the inoculum*)
contain from 2-500 mg of active compound, in a suitable
of approximately 48 hours followed by and incubation of 3 40
pharmaceutically acceptable vehicle or carrier, for adminishours with the MTS/PMS Reagent is optimal.
tration in single or multiple doses, once or several times per
*Due to the nature of the HTB123 cells it is very difficult
day. Dosages for intraveneous, buccal or sublingual adminto obtain accurate cell densities. Continuation of the
istration will typically be within the range of from 5-1000
HTB123 cell line typically consists of the dilution of mature
cells at two or three-fold into fresh media and growth at 37° 45 mg per single dose as required. In practice the physician will
determine the actual dosing regimen which will be most
C./5% C0 2 for two to three days.
suitable for an individual patient and it will vary with the
In order to establish the accuracy of this assay a Positive
age, weight and response of the particular patient. The above
Control consisting of 50 µM Methotrexate should not
dosages are exemplary of the average case but there can be
decrease the net absorbance to less than 90% of the Negative
Control (HTB123 cells are somewhat resistant to 50 individual instances in which higher or lower dosage ranges
may be merited, and such are within the scope of this
methotrexate) is utilized.
invention.
ANIMAL TOXCITY BIOASSAY
The maximum human non-toxic one time administration
dose for the compound(s) of the invention appears to range
Acute toxicity was studied on white mice of both sexes
with weight ranging between 18-26 grams under intraperi- 55 from 100 to 1500 mg.
toneal injection of 2% solution of tested compound in starch
For human use, the compounds of the invention can be
(the compound was dissolved in starch slime and injected)
administered alone or jointly, but will generally be administered in admixture with a pharmaceutical carrier selected
on the basis of 0.1 ml of solution per 10 g of the animal
with regard to the intended route of administration and
weight. Each dose was tested on the group of 6 animals that
were observed during 14 days period. (This method was 60 standard pharmaceutical practice. For example, they may be
administered orally, buccally or sublingually, in the form of
approved by the Pharmacology committee of Russian Ministry of Health and has been widely used since 1968.)
tablets containing excipients such as starch or lactose, or in
Averaged lethal dose (LD 50 ) of the compound was comcapasules or ovules either alone or in admixture with
excipients, or in the form of elixirs or suspensions containputed using results of experiments on 5-7 groups of animals
using method of Litchfield and Wilkinson. (Belenkii M. L. 65 ing flavouring or colouring agents. The compounds may also
be injected parenterally, for example intraveneously,
"Elements of quantative determination of the pharmacologiintramuscularly, subcutaneously or intracoronarily. For
cal effect," Leningrad, 1963, 71 pages).
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parenteral administration, they are best used in the form of
Taxol is perhaps best viewed as an exciting and valuable
a sterile aqueous solution which may contain other
lead in cancer chemotherapy. Although Taxol has extended
substances, for example enough salts or glucose to make the
the life of many people, it is not a cure, and many patients
solution isotonic with blood.
develop resistance to it. Many tumor types show minimal or
The invention thus provides a method for the treatment of 5 no response to Taxol, and there are solubility problems in
breast carcinoma in a human mammal which comprises
drug delivery.
administering an effective, non-toxic, amount of a heteroAccordingly, there is a need in the art for improved
cyclic compound according to the invention or a tautomeric
methods for therapy and diagnosis of breast cancer. The
form thereof and/or a pharmaceutically acceptable salt
thereof and/or a pharmaceutically acceptable solvate thereof 10 present invention fulfills these needs and further provides
other related advantages. The animal toxicity bioassay data
to a breast carcinoma invaded human mammal in need
indicated that LD 50 dose for all of the compounds are in the
thereof.
range of 250-3000 mg/kg, which is much lower compare to
ADVANTAGES OF THE INVENTION
some of the most promising agents against breast cancer. For
15 example taxol intra-peritoneal LD 50 dose in mice using the
Breast cancer is a significant health problem for women in
same bioassay system is 218 mg/kg (JZKEDZ 6,1,1980),
the United States and throughout the world. Although
which is almost a number of magnitude higher then some of
advances have been made in detection and treatment of the
the claimed compounds. Such a low toxicity dose of the
disease, breast cancer remains the second leading cause of
compounds
claimed gives a strong potential for not to
cancer-related deaths in women, affecting more than 180, 20
having such a serious side effects as the most potential drugs
000 women in the United States each year. For women in
of the present time do. Secondly, more advantages from our
North America, the life-time odds of getting breast cancer
invention are the cheapness and the simplicity of the synare now one in eight.
thesis of active compounds compare to the present drugs on
No vaccine or other universally successful method for the
the market. The synthesis of claimed compounds from
prevention or treatment of breast cancer is currently avail- 25 commercially available reagents takes four to five synthetic
able. The available drugs on the market have a variety of
steps with overall yield in the range of 60--85%. Versus for
strong side effects, high cost and complicated synthesis. For
example taxol which takes minimum of 40 synthetic steps
example, Taxol is the most promising antitumor agent
with only 2% overall yield, which increases the price of the
developed in the past three decades. It was approved by the
compound dramatically.
FDA for the treatment of refractory ovarian cancer in 30
Conclusion: Although the invented compounds have not
December, 1992, and was introduced into the marketplace in
yet been tested clinically, one can see from the Table 1 that
January, 1993 by Bristol-Myers Squibb Company (EMS)
all of them posses at least 10 times lower acute toxicity
operating under a Cooperative Research and Development
compare to the most promising antitumor agent developed in
Agreement (CRADA) with the National Cancer Institute
(NCI). It was approved for the treatment of breast cancer in 35 the past three decades, high activity values, ease of
synthesis, and cheap cost. All these advantages provide a
1994, and is now in transition from second line to first line
potential for the development of new drugs for the preventherapy. Worldwide sales of Taxol reached $1.2 billion in
tion or treatment of breast cancer.
1998. However, Preclinical development continued from
1977 until 1983, hampered by a number of obstacles,
While the invention has been described, disclosed, illusespecially the formulation problem. Taxol is highly lipo- 40 trated and shown in various terms of certain embodiments or
philic and is insoluble in water. Finally, a vehicle consisting
modifications which it has presumed in practice, the scope
of a mixture of Cremophore EL (polyethoxylated caster oil),
of the invention is not intended to be, nor should it be
ethanol and saline was chosen, but its toxicity was a sigdeemed to be, limited thereby and such other modifications
nificant problem in preclinical studies. The main side effects
or embodiments as may be suggested by the teachings herein
of this drug were found to be congenital malformation in the 45 are particularly reserved especially as they fall within the
fetus and reproductive disorders. The supply of Taxol was
breadth and scope of the claims here appended.
also a problem. To obtain Yew bark, the tree had to be killed.
We claim:
A large Pacific Yew two feet in diameter requires 200 years
1. A compound consisting of 2-(N'-Fluoren-9-ylideneto grow and yields about five pounds of bark. In extractions
by Polysciences, then the only extraction contractor, a 50 hydrazino )-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl
ester.
0.004% yield of Taxol was obtained. Furthermore, the
2. A compound consisting of 2-Hydroxy-4-oxo-4-(2,3,5,
Pacific Yew was a scarce understory tree, and its extinction
6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid.
and destruction of the old growth forests was threatened by
3. A method of treating breast carcinoma in a human in
the harvest. Few believed, because of the complexity of the
molecule, that the problem of a commercial supply of Taxol 55 need of such treatment comprising the steps of administering
to said human, in a systemic, in vitro manner, an anti-tumor
could be solved by total synthesis. The first total synthesis
effective amount of a compound of claim 1 or claim 2 having
was finally reported in 1994 by the Holton group. Although
the common property of anti-tumor activity against human
three total syntheses have been subsequently achieved by
breast cancer.
others, the Holton synthesis is the most efficient, but still
requires over 40 steps from camphor and provides an overall
yield of approximately 2%.

* * * * *

